Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Study Overview

Pfizer is running a Phase 1 study titled “PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD, CROSSOVER STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFECT OF ITRACONAZOLE ON PF-07248144 PHARMACOKINETICS.” The goal is to see how a common antifungal drug, itraconazole, changes the way the body handles Pfizer’s experimental drug PF-07248144. The study looks at how quickly PF-07248144 is absorbed, processed, and cleared from the body, and checks basic safety. For investors, this is an early but important step in de‑risking a new asset by mapping potential drug‑drug interactions.

Intervention/Treatment

The study tests two medicines. PF-07248144 is an oral tablet from Pfizer, still in early development, aimed at becoming a future commercial therapy if later trials succeed. Itraconazole is an approved antifungal drug, given as an oral solution. The trial compares PF-07248144 alone versus PF-07248144 taken together with itraconazole to see if itraconazole raises or lowers PF-07248144 levels in the blood.

Study Design

This is an interventional Phase 1 study in healthy adults. All participants receive the same treatments in sequence, so there is no random assignment to different arms. In Period 1, volunteers get a single oral dose of PF-07248144. After a washout period, Period 2 adds daily itraconazole with another single dose of PF-07248144. The study is open-label, meaning both researchers and participants know what is given. The main purpose is basic science: to understand how the drugs interact in the body rather than to test clinical benefit.

Study Timeline

The trial was first submitted on January 5, 2026, marking its formal entry into the clinical pipeline. The study status is “recruiting,” so dosing is either starting or ramping up, which signals continued commitment to PF-07248144. The most recent update was submitted on January 20, 2026, showing that Pfizer is actively maintaining the record and potentially refining operational details. Primary completion and final completion dates have not yet been posted, implying that data readouts are still some distance away and near‑term catalysts from this trial alone are limited.

Market Implications

This update confirms that Pfizer is advancing PF-07248144 through standard early-stage safety and interaction testing, a routine but necessary box to tick before larger, costlier trials. For PFE stock, the near-term impact is modest: this is a small, technical study with no immediate revenue impact, but it supports the narrative that Pfizer is rebuilding its pipeline beyond COVID-related products. The key investor takeaway is that Pfizer is investing in careful drug‑drug interaction work, which can reduce later regulatory and safety risks. In the wider industry, large pharma peers also run similar interaction studies early, so this keeps Pfizer in line with best practice rather than changing the competitive landscape. The study’s recruiting status and recent update should be viewed as a sign of steady execution rather than a major catalyst.

The study is currently ongoing and updated, with more details available on the ClinicalTrials portal under its listed identifier.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.